An Engineered Nanovesicles-Based Lysosome-Targeting Protein Degradation Platform (NV-TACs) for Cancer Immunotherapy

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Development of LYTACs via incorporating a nucleolin-targeting and lysosome-directed aptamer2025
2. 2HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking2025
3. 3HerTACs Enable Tumor‐Selective Lysosomal Degradation of Membrane and Extracellular Proteins via HER2 Trafficking2025
4. 4LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation2025
5. 5Engineered Virus‐Like Nanoparticles Enable Multimodal Protein Degradation for Enhanced Tumor Therapy2025